Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.

⁃ adult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).

Locations
United States
California
Stanford University Dept. of Medicine -Gastroenterology & Hepatology
RECRUITING
Redwood City
Time Frame
Start Date: 2025-06-10
Estimated Completion Date: 2032-03
Participants
Target number of participants: 40
Related Therapeutic Areas
Sponsors
Leads: HepQuant, LLC
Collaborators: Leland Stanford Junior University

This content was sourced from clinicaltrials.gov